Publication | Closed Access

Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-κB pathway

InflammationAngiogenesisTarget Bevacizumab EfficiencyImmunologyVascular BiologyAgr2 InterruptsNeovascularizationMedicineCell BiologyPro-metastatic ActivityTumor BiologyCancer Growth